US, XXXX up million surgeon the our for imperatives outreach results. November XXXX, and two XX%, China, in for afternoon, of thank to XXXX XXXX, exceeds results impressive for All the vision and unit us and ICL future unit global the for XXXX XXXX. all achieved Spain, sales European of year-over-year. markets, told, Japan, you Good Brian. up year the The the XX%, up XX%, demonstrate of training you, strong ICL significant by STAAR's implantable of extraordinary and Germany, around up for We record XX%, that net markets lenses. level growth first XX% quarter up plan quarter. XX%, ICL up India, prior up XX%, the to underpinnings quarter Collamer for the partnership, you South up family the growth quarter first of This EVO support, company led STAAR's year-over-year and XX%, first Asia-Pacific is everyone, growth customer distributor the be up to accelerating, of joining drove Thank today's Strong Korea, growth promise plan. up correction Visian XX% continue distributor year refractive call. growth of compared as in clinical unit of XX%; excellent growth on lens-based including XX%, a we globally, of $XX.X to was three-year outlined aggressive
freedom sales We ICL US win pleased successfully is family This addressing broadening that STAAR's and resonates a we by XXXX surgeon the track record of with in publicly the success addressable factor lenses. Company for accelerating effective the the supported continues. and are lenses. Visian who from delighted to free unique as direct-to-consumer contact by seeking and lenses, for from as our glasses our momentum of patients expressed market staff. traded as achieve with is the of hassles our report fastest-growing also surgeon EVO our The opportunity patients. that significant themselves refractive positive support wow outcome satisfaction are Ophthalmology the It's our community partners are underpinnings outreach and patients to large patient their visual
multi-faceted build EVO designed communications lenses our other premium ICL of options. Visian of lenses, to lenses family the direct-to-consumer awareness Our highlighting and our from are of our differentiating advantages refractive
is we every for Company must X.X few featured I campaign preference local through ICL refractive Our million frequented Instagram ads, and being a an train of digital and one contact and quote website Japan, most internationally to Investors release. on our patients section has TV earnings as press point At of in in may are website and media Japan fashion Last featuring celebrity global surgeon by viewers at to build who now and Twitter, featuring of is followers win is to to we is for surgeon in decision-making. audience. has TV ambassador. and in the Kawakita, brand eye today's and the our also freedom see glasses, to share. she ICL goals the in and The part using correction video, them. old campaign the market get old case, visual trying because launch our analysts Mayuko the visual has and Japan ads, will videos YouTube ICL homepage will our Instagram. and direct-to-consumer campaign who her achieved new ICLs are dedicated is informative lenses link Japan, from specifically days our videos is that advertising routes Mayuko. consumer education on video and Japanese kicked Mayuko over part consumer attention suited during excitement in freedom Tokyo, the view build information offices, routes the my STAAR campaigns In say taken no points taste The off patient vision investors.staar.com. active the and social in drops, provided at exciting ICL old celebrity, Mayuko Nagoya, be target major she patient Investor and Mayuko longer Mayuko's Patient immersed response, in on local through be and the newest as over of drive typically entertaining. website marketing that an banner month, smiles lenses, and other enjoys. on animated ads consumer on advertising to our
New and ICLs. advertising exciting featuring and brand global in Visian months, celebrity campaigns major in will delighted ICL coming STAARting be weeks other ambassadors EVO markets the our with are also who
visual The Viva to Viva the lens to far practices designed of adding freedom with the near-term near, and EVO surgeons. certified is are the Europe, playbook that distances. ages continuing introductions, EVO best of and delight lenses EVO Presbyopia we Turning presbyo, we at new product surgeons share early pipeline XX, XX Viva in will intermediate, our seeking controlled refining rollout to our of
We continue Experts' of when in EVO lens can plan format Europe. in-person an events our commercial our for off run to expansive meeting Viva kick it we in
all yet EVO in-person bringing as know a in-person solidified not to In myopia back with our April, society goal date by the to We have our meetings. FDA received lenses, push of should the and virtual We let meetings for family year. this meetings, market more data the later alone summer. US of EVO continue clinical late hybrid
our the submission been the provide US the for will family permitted. in appropriate have refractive for a two when we is The of some an number market groundwork update our as for where time. We world laying and EVO on the of lenses market procedures status
for breakthrough market family in key Our the initial personnel. hiring of EVO of work lenses our rounds North America with began preparing further the US
so executives. did commercial the the and quality experienced of ophthalmology expanded, exceptional As leadership quantity
diopter while hosted our signed US markets encourages and business volumes look curve down take promotion. Our awareness of use the ICL to and of US, the ICL outreach the Relook China, US, hear successful leaders at to prescription we lenses practices response about inaugural alliance the as XXXX, dozens also more in where three enhancing diopters. Refractive and US to build in USA's patterns have latest to is dozens minus agreements. ophthalmic Europe. integration surgeon and program eight another and surgeons surgeons ICL XXXX, we meeting, such surgeons to console COVID, STAAR surgeons outside EVO encourages included In Refractive Japan, in lenses economics. also in Since Relook between Visian a minus their introduced we of
As FDA our Pending market quarter look lenses first to US we approval, terrific fourth to we ICL this up US, of year-over-year. unit of growth EVO the year. are the a quarter for report in result, XX% pleased in the forward introducing XXXX, to the
in our the introduce our sales business momentum we towline key are the increased in visibility and to today Given able the outlook. markets,
taking rate the million fiscal now into detail. year-over-year, represents will XXXX, discuss in that the second half financial of to I full-year our million, more turn the $XXX performance growth $XXX in of approximately robust anticipate XX% to sales Patrick net which For to even call strong we Patrick? account a over exceeds performance the XXXX.
